Erratum: APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase (Cell Death and Disease (2013) 4 (e881) DOI: 10.1038/cddis.2013.417);APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase

Cell Death and Disease

Volumn 4, Issue 10, 2013, Pages

  Peng, X ^a   Zhang, M Q Z ^a   Conserva, F ^a   Hosny, G ^a   Selivanova, G ^a   Bykov, V J N ^a   Arner E S J ^a   Wiman, K G ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

APR 246; Mutant p53; PRIMA 1MET; ROS; Thioredoxin reductase 1

Indexed keywords

ANTINEOPLASTIC AGENT; APR 246; CYSTEINE; METHYLENE QUINUCLIDINONE; PROTEIN P53; QUINUCLIDINE DERIVATIVE; RECOMBINANT ENZYME; RECOMBINANT THIOREDOXIN REDUCTASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SELENOCYSTEINE; SELENOPROTEIN; THIOREDOXIN REDUCTASE 1; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ATTENUATION; CELL FUNCTION; CONTROLLED STUDY; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN TARGETING; TUMOR CELL; WILD TYPE;

ANIMALS; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; CYTOPROTECTION; GENE KNOCKDOWN TECHNIQUES; HUMANS; NADPH OXIDASE; QUINUCLIDINES; RATS; REACTIVE OXYGEN SPECIES; RNA, SMALL INTERFERING; THIOREDOXIN REDUCTASE 1;

EID: 84887417425     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2016.137     Document Type: Erratum

References (50)

1. Hussain SP, Harris CC. P53 mutation spectrum and load: The generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer. Mutat Res 1999; 428: 23-32
2. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database. Hum Mut 2007; 28: 622-629
3. Soussi T, Wiman KG. Shaping genetic alterations in human cancer: The p53 mutation paradigm. Cancer Cell 2007; 12: 303-312
4. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: Vunctional selection and impact on cancer prognosis and outcomes. Oncogene 2007; 26: 2157-2165
5. Blandino G, Levine AJ, Oren M. Mutant p53 gain of function: Differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 1999; 18: 477-485
6. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007; 445: 661-665
7. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007; 445: 656-660
8. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006; 127: 1323-1334
9. Foster BA, Coffey HA, Morin MJ, Rastinejad F. Pharmacological rescue of mutant p53 conformation and function. Science 1999; 286: 2507-2510
10. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002; 8: 282-288
11. Bykov VJ, Issaeva N, Selivanova G, Wiman KG. Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: A statistical analysis of information in the National Cancer Institute database. Carcinogenesis 2002; 23: 2011-2018
12. Bykov VJ, Zache N, Stridh H, Westman J, Bergman J, Selivanova G et al. PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. Oncogene 2005; 24: 3484-3491
13. Bykov VJ, Issaeva N, Zache N, Shilov A, Hultcrantz M, Bergman J et al. Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J Biol Chem 2005; 280: 30384-30391
14. Zache N, Lambert JM, Rokaeus N, Shen J, Hainaut P, Bergman J et al. Mutant p53 targeting by the low molecular weight compound STIMA-1. Mol Oncol 2008; 2: 70-80
15. Boeckler FM, Joerger AC, Jaggi G, Rutherford TJ, Veprintsev DB, Fersht AR. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci USA 2008; 105: 10360-10365
16. Yu X, Vazquez A, Levine AJ, Carpizo DR. Allele-specific p53 mutant reactivation. Cancer Cell 2012; 21: 614-625
17. Zache N, Lambert JM, Wiman KG, Bykov VJ. PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53. Cell Oncol 2008; 30: 411-418
18. Rokaeus N, Shen J, Eckhardt I, Bykov VJ, Wiman KG, Wilhelm MT. PRIMA-1(MET)/ APR-246 targets mutant forms of p53 family members p63 and p73. Oncogene 2010; 29: 6442-6451
19. Shen J, van den Bogaard EH, Kouwenhoven EN, Bykov VJ, Rinne T, Zhang Q et al. APR-246/PRIMA-1(MET) rescues epidermal differentiation in skin keratinocytes derived from EEC syndrome patients with p63 mutations. Proc Natl Acad Sci USA 2013; 110: 2157-2162
20. Lehmann S, Bykov VJ, Ali D, Andren O, Cherif H, Tidefelt U et al. Targeting p53 in vivo: A first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol 2012; 30: 3633-3639
21. Lambert JM, Gorzov P, Veprintsev DB, Soderqvist M, Segerback D, Bergman J et al. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 2009; 15: 376-388
22. Arner ES. Focus on mammalian thioredoxin reductases - important selenoproteins with versatile functions. Biochim Biophys Acta 2009; 1790: 495-526
23. Arné r ESJ. Selenoproteins -What unique properties can arise with selenocysteine in place of cysteine? Exp Cell Res 2010; 316: 1296-1303
24. Sasada T, Nakamura H, Ueda S, Sato N, Kitaoka Y, Gon Y et al. Possible involvement of thioredoxin reductase as well as thioredoxin in cellular sensitivity to cis-diamminedichloroplatinum (II). Free Radic Biol Med 1999; 27: 504-514
25. Tonissen KF, Di Trapani G. Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy. Mol Nutr Food Res 2009; 53: 87-103
26. Anestal K, Arner ES. Rapid induction of cell death by selenium-compromised thioredoxin reductase 1 but not by the fully active enzyme containing selenocysteine. J Biol Chem 2003; 278: 15966-15972
27. Anestal K, Prast-Nielsen S, Cenas N, Arner ES. Cell death by SecTRAPs: Thioredoxin reductase as a prooxidant killer of cells. PLoS One 2008; 3: E1846
28. Arné r ESJ, Holmgren A. Measurement of thioredoxin and thioredoxin reductase. In: Costa LG (ed) Current Protocols in Toxicology. Wiley: Hoboken, NJ, USA, 2000. pp 7.4.1-7.4.14
29. Ramqvist T, Magnusson KP, Wang Y, Szekely L, Klein G, Wiman KG. Wild-type p53 induces apoptosis in a Burkitt lymphoma (BL) line that carries mutant p53. Oncogene 1993; 8: 1495-1500
30. Witte AB, Anestal K, Jerremalm E, Ehrsson H, Arner ES. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radic Biol Med 2005; 39: 696-703
31. Fang J, Lu J, Holmgren A. Thioredoxin reductase is irreversibly modified by curcumin. J Biol Chem 2005; 280: 25284-25290
32. Lu J, Papp LV, Fang J, Rodriguez-Nieto S, Zhivotovsky B, Holmgren A. Inhibition of mammalian thioredoxin reductase by some flavonoids: Implications for myricetin and quercetin anticancer activity. Cancer Res 2006; 66: 4410-4418
33. Biaglow JE, Miller RA. The thioredoxin reductase/thioredoxin system: Novel redox targets for cancer therapy. Cancer Biol Ther 2005; 4: 6-13
34. Prigge JR, Eriksson S, Iverson SV, Meade TA, Capecchi MR, Arner ES et al. Hepatocyte DNA replication in growing liver requires either glutathione or a single allele of txnrd1.Free Radic Biol Med 2012; 52: 803-810
35. Bondareva AA, Capecchi MR, Iverson SV, Li Y, Lopez NI, Lucas O et al. Effects of thioredoxin reductase-1 deletion on embryogenesis and transcriptome. Free Radic Biol Med 2007; 43: 911-923
36. Suvorova ES, Lucas O, Weisend CM, Rollins MF, Merrill GF, Capecchi MR et al. Cytoprotective Nrf2 pathway is induced in chronically txnrd 1-deficient hepatocytes. PLoS One 2009; 4: E6158
37. Mandal PK, Schneider M, Kolle P, Kuhlencordt P, Forster H, Beck H et al. Loss of thioredoxin reductase 1 renders tumors highly susceptible to pharmacologic glutathione deprivation. Cancer Res 2010; 70: 9505-9514
38. Locy ML, Rogers LK, Prigge JR, Schmidt EE, Arner ES, Tipple TE. Thioredoxin reductase inhibition elicits Nrf2-mediated responses in Clara cells: Implications for oxidant-induced lung injury. Antioxidants Redox Signal 2012; 17: 1407-1416
39. Bykov VJ, Lambert JM, Hainaut P, Wiman KG. Mutant p53 rescue and modulation of p53 redox state. Cell Cycle 2009; 8: 2509-2517
40. Johnson TM, Yu ZX, Ferrans VJ, Lowenstein RA, Finkel T. Reactive oxygen species are downstream mediators of p53-dependent apoptosis. Proc Natl Acad Sci USA 1996; 93: 11848-11852
41. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature 1997; 389: 300-305
42. Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE, Chumakov PM. The antioxidant function of the p53 tumor suppressor. Nat Med 2005; 11: 1306-1313
43. Marchenko ND, Zaika A, Moll UM. Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling. J Biol Chem 2000; 275: 16202-16212
44. Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature 2009; 458: 1127-1130
45. Tomita Y, Marchenko N, Erster S, Nemajerova A, Dehner A, Klein C et al. WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization. J Biol Chem 2006; 281: 8600-8606
46. Lincoln DT, Ali Emadi EM, Tonissen KF, Clarke FM. The thioredoxin-thioredoxin reductase system: over-expression in human cancer. Anticancer Res 2003; 23: 2425-2433
47. Moos PJ, Edes K, Cassidy P, Massuda E, Fitzpatrick FA. Electrophilic prostaglandins and lipid aldehydes repress redox-sensitive transcription factors p53 and hypoxiainducible factor by impairing the selenoprotein thioredoxin reductase. J Biol Chem 2003; 278: 745-750
48. Hedstrom E, Eriksson S, Zawacka-Pankau J, Arner ES, Selivanova G. P53-dependent inhibition of TrxR1 contributes to the tumor-specific induction of apoptosis by RITA. Cell Cycle 2009; 8: 3576-3583
49. Xu J, Arner ES. Pyrroloquinoline quinone modulates the kinetic parameters of the mammalian selenoprotein thioredoxin reductase 1 and is an inhibitor of glutathione reductase. Biochem Pharmacol 2012; 83: 815-820
50. Eriksson SE, Prast-Nielsen S, Flaberg E, Szekely L, Arner ESJ. High levels of thioredoxin reductase 1 modulate drug-specific cytotoxic efficacy. Free Rad Biol Med 2009; 47: 1661-1671